Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Update

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the recipient of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 94,000 shares, a decline of 68.2% from the October 15th total of 295,800 shares. Based on an average daily volume of 761,400 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.0% of the shares of the company are sold short.

Entero Therapeutics Price Performance

Shares of ENTO traded up $0.01 during trading hours on Wednesday, hitting $0.63. The company had a trading volume of 1,777,547 shares, compared to its average volume of 365,110. The stock has a fifty day moving average price of $0.49. Entero Therapeutics has a 12 month low of $0.19 and a 12 month high of $14.51.

Entero Therapeutics (NASDAQ:ENTO) last released its quarterly earnings results on Monday, October 21st. The company reported ($3.37) earnings per share for the quarter. Analysts predict that Entero Therapeutics will post -1.13 earnings per share for the current fiscal year.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.